Amgen Inc.
AMGN Large CapHealthcare · Drug Manufacturers - General
Updated: Jun 14, 2026, 22:19 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatmen
Amgen Inc. Stock at a Glance
Amgen Inc. (AMGN) is currently trading at $355.20 with a market capitalization of $191.7B. The trailing P/E ratio stands at 24.68x, with a forward P/E of 15.13x. The 52-week range spans from $267.83 to $391.29; the current price is 9.2% below the yearly high. Year-over-year revenue growth stands at +5.8%. The net profit margin stands at 20.96%.
💰 Dividend
Amgen Inc. pays an annual dividend of $10.08 per share, representing a yield of 2.84%. The payout ratio stands at 67.22%.
📊 Analyst Rating
30 analysts rate Amgen Inc. (AMGN) on consensus: Buy. The average price target is $352.50, implying -0.76% from the current price. Analyst price targets range from $200.00 to $427.00.
Amgen Inc.: The Investment Case in Detail
Amgen Inc. (AMGN) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
With a gross margin near 71.44%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 101.32% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 20.96%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.
The Bear Case
The debt-to-equity ratio of 623.75% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.
What to Watch Next
- The forward P/E of 15.13x is meaningfully below the trailing 24.68x — analysts expect earnings to step up; the next earnings release is the test.
Investment Thesis: Strengths & Weaknesses
- Profitable with 20.96% net margin
- High return on equity (101.32% ROE)
- High gross margin of 71.44% — indicates pricing power
- Analyst consensus: Buy
- Solid dividend yield of 2.84%
- Positive free cash flow
- –High leverage (D/E 623.75)
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to relatively defensive market behavior, higher leverage relative to equity.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Amgen Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news